Cyndeo Wealth Partners LLC Decreases Stock Position in Abbott Laboratories $ABT

Cyndeo Wealth Partners LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 8.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,061 shares of the healthcare product maker’s stock after selling 15,532 shares during the period. Abbott Laboratories makes up 1.1% of Cyndeo Wealth Partners LLC’s portfolio, making the stock its 19th biggest position. Cyndeo Wealth Partners LLC’s holdings in Abbott Laboratories were worth $20,054,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after acquiring an additional 689,517 shares in the last quarter. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after acquiring an additional 1,478,076 shares in the last quarter. Norges Bank purchased a new position in Abbott Laboratories in the second quarter valued at about $3,026,180,000. Massachusetts Financial Services Co. MA grew its stake in Abbott Laboratories by 5.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after purchasing an additional 821,325 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $105.58 on Friday. The stock’s 50 day simple moving average is $112.75 and its 200 day simple moving average is $123.03. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The firm has a market cap of $183.88 billion, a P/E ratio of 28.38, a P/E/G ratio of 1.68 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the company posted $1.34 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABT. Argus reduced their target price on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Royal Bank Of Canada dropped their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Piper Sandler dropped their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the transaction, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott expects to close its acquisition of Exact Sciences on March 23, 2026, after receiving all regulatory clearances — a major strategic move that immediately expands Abbott’s presence in cancer screening and diagnostics and could drive revenue growth over time. Abbott acquisition of Exact Sciences set to close on March 23, 2026
• Positive Sentiment: Coverage and commentary highlight the strategic expansion into diagnostics with Exact Sciences, positioning Abbott to capture a larger share of growing cancer-screening markets — a long-term revenue and pipeline positive. Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures
• Positive Sentiment: Independent bullish write-ups (syndicated on Yahoo/InsiderMonkey) recap a bullish thesis on ABT, citing valuation metrics and growth potential tied to diagnostics exposure — such coverage can support investor interest and longer-term upside. Is Abbott Laboratories (ABT) A Good Stock To Buy Now?
• Neutral Sentiment: Macro/theme-level research (UBS longevity thematic piece) frames aging and longevity as structural tailwinds for companies exposed to diagnostics and chronic-care solutions; this supports ABT’s long-term thesis but is not an immediate catalyst. Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates
• Negative Sentiment: Healthcare stocks pulled back late Friday, dragging ABT with the sector; broader sector weakness can amplify short-term downside even when company-specific news is positive. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: Relative underperformance versus peers was noted in market reports — investors may be trimming ABT into the acquisition close due to integration, execution and dilution concerns. Abbott Laboratories stock underperforms Friday when compared to competitors

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.